Hyperactivation of the Wnt/beta-catenin pathway may confer resistance to inhibitors of PI3K and Akt [26], and cancers with CTNNB1 mutations are presumed to be resistant also to pharmacologic inhibition of upstream components of the WNT pathway [27]. This evidence concerns the gene AKT1 and cancer.